Novo Nordisk Lays Out Obesity Commercial Strategy, Ahead of Liraglutide FDA Submission
This article was originally published in The Pink Sheet Daily
Reimbursement and sales strategy for liraglutide 3 mg to treat obesity, which the pharma hopes to launch in 2015, are a focus as the pharma laid out its long-term plans in an analyst meeting on Dec. 3. It suggested payers, who aren’t embracing new obesity drugs, could try patients on the drug for a trial period and proceed only with the best responders.
You may also be interested in...
Contrave could be approved by FDA in 2014, making it the third obesity therapeutic to reach the market in the last two years. An interim analysis of the CV outcomes study LIGHT demonstrates a favorable risk-benefit profile, management said.
Novo Nordisk reported positive data from a Phase III trial of liraglutide in sleep apnea, completing the drug’s clinical program in obesity. It expects to file for regulatory approval of the drug as a weight reducer by year end.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?